US tobacco giant Philip Morris has failed in its challenge before IP Australia to rival British American Tobacco’s application for a trade mark to be used on its electronic cigarettes.
Beverage giant Monster Energy has appealed a ruling that allowed a company associated with leading tyre retailer Bob Jane T-Mart to register trade marks for its Monster brand alloy wheels.
A court has barred US drug company Merck Sharp & Dohme from denying that an agreement made with German pharmaceutical company Merck KGaA was governed by German law, settling a key question before a trade mark case between the two drug giants goes to trial.
A court has found Ariosa Diagnostics infringed a patent held by Sequenom for a noninvasive prenatal genetic test, and ruled one claim of the patent invalid for lack of fair basis.
A judge has allowed a company associated with leading tyre retailer Bob Jane T-Mart to register three trade marks for its brand of Monster alloy wheels, dismissing claims from US energy drink giant Monster Energy that allowing the registration would lead to confusion.
A developer of what’s now being called the “Infamous Mod” for video game Grand Theft Auto, which gives players extra powers, is confident he can defend the copyright case brought against him by Take-Two Interactive and its subsidiary Rockstar Games.
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.
Drug maker Janssen will drop its long-running patent lawsuit against Alphapharm after the generic drug maker agreed to refrain from making products that allegedly infringe Janssen’s patents for its HIV drug Prezista.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.